Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in San Francisco, California

This page shows live ClinicalTrials.gov search results for San Francisco, California, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
5126
Shown on this page
12
Current sort
Recently updated
Location scope
San Francisco, CA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within San Francisco, California. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 145–156 of 5,126 matching trials in San Francisco, CA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in San Francisco

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Phase 3 Interventional

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Zanidatamab, Cisplatin, Gemcitabine, Pembrolizumab, Durvalumab
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
21
States / cities
Duarte, California • Lone Tree, Colorado • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:30 PM EST
Recruiting No phase listed Observational

Pompe Disease Registry Protocol

NCT00231400
View directory record Official record
Conditions
Glycogen Storage Disease Type II, Pompe Disease
Interventions
Not listed
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2034
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:30 PM EST
Recruiting Phase 1 Interventional

Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors

NCT04855656
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Lunresertib, RP-3500, Zedoresertib
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:30 PM EST
Recruiting Phase 1Phase 2 Interventional

A Study of TAK-505 in Adults With Solid Tumors

NCT07436728
View directory record Official record
Conditions
Malignant Solid Tumors
Interventions
TAK-505
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
15
States / cities
Orange, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:30 PM EST
Completed No phase listed Observational

Clinical Evaluation of the i-STAT ACTpro Cartridge in an Adult Population

NCT07382076
View directory record Official record
Conditions
Activated Clotting Time
Interventions
Blood draw
Diagnostic Test
Lead sponsor
Abbott Point of Care
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Chandler, Arizona • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:30 PM EST
Recruiting Phase 3 Interventional

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654
View directory record Official record
Conditions
Extrapulmonary Neuroendocrine Cancer (epNEC)
Interventions
Obrixtamig, Carboplatin, Etoposide, Ventana DLL3 RxDx assay
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 5:30 PM EST
Recruiting Phase 2 Interventional

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

NCT07473700
View directory record Official record
Conditions
Hypertension, Pulmonary, Lung Diseases, Interstitial
Interventions
TX000045
Drug
Lead sponsor
Tectonic Operating Company, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • San Francisco, California • Boise, Idaho + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 4, 2026, 5:30 PM EST
Recruiting Not applicable Interventional

Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD

NCT05572632
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
COPD Wellness, COPD Wellness Plus+, Usual Care
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 90 Years
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 4, 2026, 5:30 PM EST
Active, not recruiting Not applicable Interventional

Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)

NCT05051033
View directory record Official record
Conditions
Mitral Valve Regurgitation
Interventions
Mitral valve repair, Transcatheter edge-to-edge repair
Procedure · Device
Lead sponsor
Annetine Gelijns
Other
Eligibility
60 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 4, 2026, 5:30 PM EST
Active, not recruiting Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

NCT01856192
View directory record Official record
Conditions
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
502
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 349 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 4, 2026, 5:30 PM EST
Recruiting Not applicable Interventional

Focused Ultrasound for Behavioral Health

NCT07851038
View directory record Official record
Conditions
Depression, Anxiety, Obsessive Compulsive Disorder (OCD)
Interventions
ATTN201 head-worn focused ultrasound
Device
Lead sponsor
Attune Neurosciences Inc
Industry
Eligibility
22 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 4, 2026, 5:30 PM EST
Recruiting Phase 2 Interventional

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

NCT07415031
View directory record Official record
Conditions
Solid Tumors
Interventions
Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel, Irinotecan, Leucovorin, Oxaliplatin, Fluorouracil
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Phoenix, Arizona • Bellflower, California • Long Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 4, 2026, 5:30 PM EST